Certis Oncology Presented Cancer Research at AACR Annual Meeting
San Diego, Calif. — April 10, 2024 – Certis Oncology presented its latest transformational cancer research at the 2024 Annual Meeting of the American Association for Cancer Research April 7-10 at the San Diego Convention Center.
At this year’s event, Certis scientists highlighted the applications of the company’s patent-pending, predictive artificial intelligence/machine learning (AI/ML) platform, CertisAI™ for precision medicine and early drug development, and illustrated the importance of using clinically relevant preclinical models when testing cell therapies and researching difficult-to-treat brain cancers.
Four Certis scientific posters were presented.
• Assessing Machine Learning Models of Drug Response Predictions Using Orthotopic Patient-Derived Xenografts
• Integrating Artificial Intelligence and Functional Precision Oncology for Individualized Cancer Therapies
• Evaluation Of Autologous and Allogeneic T-Cell-Based Therapies in Ex Vivo And In Vivo Xenograft Tumors
• A Multi-Targeted Approach to Evaluate Therapeutic Selection and Efficacy in Preclinical Glioblastoma (GBM) Models
Abstracts and PDF downloads of all posters are available here.
MEDIA CONTACT
Certis Oncology Solutions
Kristein King
kking@certisoncology.com
573-818-4528